From: Circulating tumour DNA alterations: emerging biomarker in head and neck squamous cell carcinoma
Generation | Scale of analysis | Examples of technologies | Applications | Advantages | Disadvantages |
---|---|---|---|---|---|
First generation and next generation sequencing | Single locus or limited multiplex assays | PCR-based: · Droplet Digital PCR (ddPCR) [140] · BEAMING [31] · Intplex [149] | · Detection and quantification of selected loci, cancer hotspot mutations and small number of mutations | · Widely used · High sensitivity | · Sampling error can happen when samples need to split into multiple reactions · Very low copy numbers of mutant DNA impairs the overall performance · Only detects previously known mutations |
Enrichment for mutant alleles: · COLD-PCR [82] · SCODA [95] · NaME-PRO [136] | |||||
Next generation sequencing | Targeted sequencing assays | Amplicon-based method: · SiMSen-Seq [144] · TAM-Seq [38] · Enhanced TAM-Seq [41] · Safe-SeqS [71] ·AmpliSeq [143] ·MiSeq [69] ·NextSeq [67] ·HaloPlex [83] | · Genotyping · Interrogating numerous mutations (SNP, CNV, insertion, deletion, structural variation) ·Individual exons of interest to the whole exome | · Reduced background error rates because of higher coverage compared to WGS · Detection of allele fractions below 0.1% · Even with limited amounts of input samples, sensitivity can be further enhanced | · Only detecting mutations in targeted genes/locations · Limited detection of fusions |
Hybridization capture: · CAPP-Seq [104] · TARDIS [97] · SureSelect [74] · SeqCap [26] · HiSeq [81] | |||||
Non-targeted assays or Genome-wide | Whole genome sequencing (WGS): · Plasma-Seq [58] · PARE [75] | · Identification of amplifications and deletions · Detection of fetal aneuploidies | · Investigation of genomic alterations without previously knowledge · Characterization of the whole molecular landscape | · Limited detection in low tumour purity samples (< 25%) allele fractions sensitivity poor below low coverage · Limited sensitivity for profiling early-stage cancer · High cost | |
Amplicon-based: · FAST-SeqS [70] · mFast-SeqS [9] | |||||
Third generation sequencing | Targeted and whole genome sequencing | · Oxford Nanopore Technology (ONT) · CyclomicsSeq [92] | ·Detection of a wide range of variants from SNV to structural variants · Methylation of cfDNA | · Rapid turnaround time · Flexible accessibility · Cost-effective · Unrestricted read length (20 bp to 4 Mb) | · Relatively high error rates |